MYC and Familial prostate cancer: Furthermore, a recent study has provided preclinical evidence demonstrating improved therapeutic efficacy in preclinical models of MYC-driven prostate cancer upon combined treatment of CX-5461 and an inhibitor of PIM kinase [106].